, Seiji Protein Kinase C Protein Kinase A as Another Mediator of Ischemic Preconditioning Independent of

Hiroko Okuda, Hiroaki Shimokawa, Hitonobu Tomoike, Masatsugu Hori and Masafumi Takashima, Tomi Fukushima, Akiko Ogai, Yoshiro Shinozaki, Masashi Fujita, Akio Hirata, Shoji Sanada, Hiroshi Asanuma, Osamu Tsukamoto, Tetsuo Minamino, Koichi Node, Seiji Protein Kinase C Protein Kinase A as Another Mediator of Ischemic Preconditioning Independent of Print ISSN: 0009-7322. Online ISSN: 1524-4539 Copyright © 2004 American Heart Association, Inc. All rights reserved. is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231 Circulation doi: 10.1161/01.CIR.0000133390.12306.C7 2004;110:51-57; originally published online June 21, 2004; Circulation. http://circ.ahajournals.org/content/110/1/51 World Wide Web at: The online version of this article, along with updated information and services, is located on the

[1]  S. Sanada,et al.  Ischemic preconditioning: emerging evidence, controversy, and translational trials. , 2004, International journal of cardiology.

[2]  S. Mieno,et al.  Repetitive preischemic infusion of phosphodiesterase III inhibitor olprinone elicits cardioprotective effects in the failing heart after myocardial infarction , 2003, Molecular and Cellular Biochemistry.

[3]  R. Strasser,et al.  Ischemic preconditioning promotes a transient, but not sustained translocation of protein kinase C and sensitization of adenylyl cyclase , 2003, Basic Research in Cardiology.

[4]  M. Gimona,et al.  Protein Kinase C Induces Actin Reorganization via a Src- and Rho-dependent Pathway* , 2002, The Journal of Biological Chemistry.

[5]  M. Jo,et al.  Cooperativity between the Ras-ERK and Rho-Rho Kinase Pathways in Urokinase-type Plasminogen Activator-stimulated Cell Migration* , 2002, The Journal of Biological Chemistry.

[6]  J. Michel,et al.  Lovastatin Enhances Ecto-5′-Nucleotidase Activity and Cell Surface Expression in Endothelial Cells: Implication of Rho-Family GTPases , 2002, Circulation research.

[7]  H. Shimokawa.  Rho-kinase as a Novel Therapeutic Target in Treatment of Cardiovascular Diseases , 2002, Journal of cardiovascular pharmacology.

[8]  H. Shimokawa,et al.  Antianginal effects of hydroxyfasudil, a Rho‐kinase inhibitor, in a canine model of effort angina , 2001, British journal of pharmacology.

[9]  M. Hori,et al.  Cardioprotective Effect Afforded by Transient Exposure to Phosphodiesterase III Inhibitors: The Role of Protein Kinase A and p38 Mitogen-Activated Protein Kinase , 2001, Circulation.

[10]  Y. Kataoka,et al.  Protein kinase C-catalyzed phosphorylation of an inhibitory phosphoprotein of myosin phosphatase is involved in human platelet secretion. , 2001, Blood.

[11]  M. Hori,et al.  Role of Phasic Dynamism of p38 Mitogen-Activated Protein Kinase Activation in Ischemic Preconditioning of the Canine Heart , 2001, Circulation research.

[12]  M. Hori,et al.  Protein Tyrosine Kinase Is Not Involved in the Infarct Size–Limiting Effect of Ischemic Preconditioning in Canine Hearts , 2000, Circulation research.

[13]  R. Lefkowitz,et al.  Overexpression of the cardiac beta(2)-adrenergic receptor and expression of a beta-adrenergic receptor kinase-1 (betaARK1) inhibitor both increase myocardial contractility but have differential effects on susceptibility to ischemic injury. , 1999, Circulation research.

[14]  P. Ping,et al.  Demonstration of selective protein kinase C-dependent activation of Src and Lck tyrosine kinases during ischemic preconditioning in conscious rabbits. , 1999, Circulation research.

[15]  A. Takeshita,et al.  Rho-kinase-mediated pathway induces enhanced myosin light chain phosphorylations in a swine model of coronary artery spasm. , 1999, Cardiovascular research.

[16]  J. Downey,et al.  Ischemic preconditioning depends on interaction between mitochondrial KATP channels and actin cytoskeleton. , 1999, American journal of physiology. Heart and circulatory physiology.

[17]  M. Moskowitz,et al.  Neuroprotective effects of gelsolin during murine stroke. , 1999, The Journal of clinical investigation.

[18]  L. Lim,et al.  cAMP-induced Morphological Changes Are Counteracted by the Activated RhoA Small GTPase and the Rho Kinase ROKα* , 1998, The Journal of Biological Chemistry.

[19]  S. Motomura,et al.  Time course of a new ultrashort-acting beta-adrenoceptor-blocking drug, ONO-1101: comparison with those of esmolol and propranolol by using the canine isolated, blood-perfused heart preparations. , 1998, Journal of cardiovascular pharmacology.

[20]  Shuh Narumiya,et al.  Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension , 1997, Nature.

[21]  K. S. Lee,et al.  Proliferation of hepatic stellate cells is inhibited by phosphorylation of CREB on serine 133. , 1997, The Journal of clinical investigation.

[22]  M. Hori,et al.  Activation of ecto‐5′‐nucleotidase by protein kinase C and its role in ischaemic tolerance in the canine heart , 1997, British journal of pharmacology.

[23]  A. Terzic,et al.  Actin microfilament disrupters enhance K(ATP) channel opening in patches from guinea‐pig cardiomyocytes. , 1996, The Journal of physiology.

[24]  R. Braun-Dullaeus,et al.  Alpha 1-receptor-independent activation of protein kinase C in acute myocardial ischemia. Mechanisms for sensitization of the adenylyl cyclase system. , 1992, Circulation research.

[25]  M. Hagiwara,et al.  Inhibition of forskolin-induced neurite outgrowth and protein phosphorylation by a newly synthesized selective inhibitor of cyclic AMP-dependent protein kinase, N-[2-(p-bromocinnamylamino)ethyl]-5-isoquinolinesulfonamide (H-89), of PC12D pheochromocytoma cells. , 1990, The Journal of biological chemistry.

[26]  C. Strader,et al.  Identification of a specific site required for rapid heterologous desensitization of the beta-adrenergic receptor by cAMP-dependent protein kinase. , 1989, Molecular pharmacology.

[27]  T. Voyno-Yasenetskaya,et al.  Protein kinase A-mediated phosphorylation of the Galpha13 switch I region alters the Galphabetagamma13-G protein-coupled receptor complex and inhibits Rho activation. , 2003, The Journal of biological chemistry.

[28]  M. Hori,et al.  Role of mitochondrial and sarcolemmal K(ATP) channels in ischemic preconditioning of the canine heart. , 2001, American journal of physiology. Heart and circulatory physiology.

[29]  M. Moskowitz,et al.  Neuroprotection mediated by changes in the endothelial actin cytoskeleton. , 2000, The Journal of clinical investigation.

[30]  A. Lochner,et al.  Ischemic preconditioning and the beta-adrenergic signal transduction pathway. , 1999, Circulation.

[31]  R. J. Diaz,et al.  Effect of ischemic preconditioning of the myocardium on cAMP. , 1996, Circulation research.

[32]  J. Papp,et al.  Long-term ischaemic preconditioning of the heart induced by repeated beta-adrenergic stress. , 1996, Acta physiologica Hungarica.

[33]  B. Jastorff,et al.  cAMP analog antagonists of cAMP action. , 1988, Methods in enzymology.